Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass.

Atebimetinib, a dual-MEK inhibitor, demonstrates broad activity in RAS- and RAF-mutant tumors through deep cyclic inhibition, resisting CRAF bypass and showing improved efficacy.

• Why it matters: Inappropriate MAPK pathway activation from RAS or RAF mutations is a common oncogenic event, but current inhibitors target only specific mutants and cause toxicities, limiting treatment options.
• What they did: The study designed atebimetinib to resist CRAF bypass and employ deep cyclic inhibition (DCI), a pharmacokinetic/pharmacodynamic approach that transiently suppresses oncogenic signaling with daily recovery periods, tested in vitro and in xenograft models.
• The result: Atebimetinib potently inhibited ERK phosphorylation, was well tolerated, and more effective than existing MEK inhibitors, suggesting its potential for durable, mutation-agnostic MAPK pathway inhibition with fewer toxicities.